Logo

Novartis Report Results of Kesimpta (ofatumumab) Sensoready Autoinjector Pen for Multiple Sclerosis

Share this

Novartis Report Results of Kesimpta (ofatumumab) Sensoready Autoinjector Pen for Multiple Sclerosis

Shots:

  • The multicenter survey involves assessing Kesimpta Sensoready autoinjector pen in 80 MS patients and 50 MS nurses- with RMS who received a disease modifying treatment through a subcutaneous/intramuscular injection via an autoinjector
  • The result shows MS patients and nurses prefer the Kesimpta Sensoready autoinjector pen over other autoinjectors for current treatment (84% vs 16%). The findings will be presented at the ACTRIMS Forum 2021 on Feb- 2021
  • Kesimpta received positive CHMP opinion last month based on two P-III trials showed reduction of annual relapses by over 50% with more than 30% relative risk reduction of 3 mos. CDP vs teriflunomide

 ­ Ref: Novartis | Image: Novartis 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions